BR112015003033B1 - Composto, composição farmacêutica e uso do composto - Google Patents
Composto, composição farmacêutica e uso do composto Download PDFInfo
- Publication number
- BR112015003033B1 BR112015003033B1 BR112015003033-5A BR112015003033A BR112015003033B1 BR 112015003033 B1 BR112015003033 B1 BR 112015003033B1 BR 112015003033 A BR112015003033 A BR 112015003033A BR 112015003033 B1 BR112015003033 B1 BR 112015003033B1
- Authority
- BR
- Brazil
- Prior art keywords
- group
- 2xch2
- compound
- chosen
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1257856A FR2994572B1 (fr) | 2012-08-17 | 2012-08-17 | Pyrido[3,2-d]pyrimidines trisubstituees, leurs procedes de preparation et leurs utilisation en therapeutique |
| FR1257856 | 2012-08-17 | ||
| PCT/EP2013/067129 WO2014027081A1 (fr) | 2012-08-17 | 2013-08-16 | Pyrido[3,2-d]pyrimidines trisubstituées, leurs procédés de préparation et leurs utilisations en thérapeutique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015003033A2 BR112015003033A2 (pt) | 2017-08-08 |
| BR112015003033B1 true BR112015003033B1 (pt) | 2022-11-16 |
Family
ID=47088936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015003033-5A BR112015003033B1 (pt) | 2012-08-17 | 2013-08-16 | Composto, composição farmacêutica e uso do composto |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10202372B2 (fr) |
| EP (1) | EP2885297B1 (fr) |
| KR (1) | KR20150046155A (fr) |
| CN (1) | CN104718203A (fr) |
| AU (2) | AU2013304046A1 (fr) |
| BR (1) | BR112015003033B1 (fr) |
| CA (1) | CA2881110A1 (fr) |
| ES (1) | ES2655284T3 (fr) |
| FR (1) | FR2994572B1 (fr) |
| WO (1) | WO2014027081A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107698587A (zh) * | 2017-11-08 | 2018-02-16 | 贵州医科大学 | 杂环并嘧啶二酮类化合物制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0415367D0 (en) * | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
| WO2006135993A1 (fr) | 2005-06-24 | 2006-12-28 | Gilead Sciences, Inc. | Pyrido(3,2-d)pyrimidines et compositions pharmaceutiques destinees au traitement de l'hepatite c |
| CA2661436A1 (fr) | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Derives d'isoquinoline, quinazoline et phtalazine |
| ES2385692T3 (es) * | 2007-07-09 | 2012-07-30 | Astrazeneca Ab | Derivados de morfolino pirimidina usados en enfermedades relacionadas con mTOR quinasa y/o PI3K |
| UY32582A (es) * | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
| MX2011012584A (es) * | 2009-05-26 | 2012-02-21 | Exelixis Inc | Benzoxazepinas como inhibidores de pi3k/m tor, metodos para su uso y fabricación. |
| US8440651B2 (en) * | 2010-02-22 | 2013-05-14 | F. Hoffmann-La Roche Ag | Pyrido[3,2-d]pyrimidine PI3K delta inhibitor compounds and methods of use |
| FR2959510B1 (fr) * | 2010-04-28 | 2013-04-26 | Centre Nat Rech Scient | Derives de pyrido[3,2-d]pyrimidine, leurs procedes de preparation et leurs utilisations therapeutiques |
| WO2012058671A1 (fr) * | 2010-10-31 | 2012-05-03 | Endo Pharmaceuticals Inc. | Dérivés de quinazoline et de pyrido-pyrimidine substituées |
-
2012
- 2012-08-17 FR FR1257856A patent/FR2994572B1/fr active Active
-
2013
- 2013-08-16 EP EP13750072.4A patent/EP2885297B1/fr active Active
- 2013-08-16 CN CN201380049835.XA patent/CN104718203A/zh active Pending
- 2013-08-16 CA CA2881110A patent/CA2881110A1/fr active Pending
- 2013-08-16 ES ES13750072.4T patent/ES2655284T3/es active Active
- 2013-08-16 AU AU2013304046A patent/AU2013304046A1/en not_active Abandoned
- 2013-08-16 WO PCT/EP2013/067129 patent/WO2014027081A1/fr active Application Filing
- 2013-08-16 BR BR112015003033-5A patent/BR112015003033B1/pt active IP Right Grant
- 2013-08-16 KR KR20157006805A patent/KR20150046155A/ko not_active Application Discontinuation
- 2013-08-16 US US14/421,402 patent/US10202372B2/en active Active
-
2017
- 2017-12-06 AU AU2017272233A patent/AU2017272233A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20150203489A1 (en) | 2015-07-23 |
| AU2017272233A1 (en) | 2018-01-04 |
| US10202372B2 (en) | 2019-02-12 |
| AU2013304046A1 (en) | 2015-02-26 |
| WO2014027081A1 (fr) | 2014-02-20 |
| FR2994572B1 (fr) | 2015-04-17 |
| ES2655284T3 (es) | 2018-02-19 |
| BR112015003033A2 (pt) | 2017-08-08 |
| CA2881110A1 (fr) | 2014-02-20 |
| FR2994572A1 (fr) | 2014-02-21 |
| EP2885297B1 (fr) | 2017-10-11 |
| KR20150046155A (ko) | 2015-04-29 |
| CN104718203A (zh) | 2015-06-17 |
| EP2885297A1 (fr) | 2015-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017289158B2 (en) | 4,6-diaminoquinazolines as Cot modulators and methods of use thereof | |
| AU2017268536B2 (en) | Novel compounds and compositions for inhibition of FASN | |
| EP2958898B1 (fr) | Derives de 2-(hetero)aryl-benzimidazole and imidazopyridine comme inhibiteur de asparagine methyl transferase | |
| KR20150121007A (ko) | 트리플루오르메틸-치환된 고리-융합된 피리미딘 및 그의 용도 | |
| JP2016510042A (ja) | ピリドピリミジンまたはピリミドピリミジン系化合物、その製造方法、薬剤組成物及びその用途 | |
| JP2019089762A (ja) | ベンゾオキサゼピン化合物の作製方法 | |
| EP2396325B1 (fr) | Dérivés d'azaindoles comme inhibiteurs des protéines kinases abl et src | |
| MX2010013606A (es) | Diazacarbazoles y metodos de uso. | |
| ES2818529T3 (es) | Derivados de bencimidazol como inhibidores Nav 1.7 (subunidad alfa del canal de sodio, dependiente del voltaje, tipo IX (SCN9A)) para tratar el dolor, la disuria y la esclerosis múltiple | |
| CN112094269B (zh) | 一类饱和六元环并杂环类化合物、制备方法和用途 | |
| CN104411696A (zh) | 环己烷-1,2′-萘-1′,2″-咪唑化合物及其作为bace抑制剂的用途 | |
| AU2015286049A1 (en) | Aromatic heterocyclic derivatives and pharmaceutical applications thereof | |
| EA036819B1 (ru) | 7-(МОРФОЛИНИЛ)-2-(N-ПИПЕРАЗИНИЛ)МЕТИЛТИЕНО[2,3-c]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПРОТИВОРАКОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ | |
| BR112020026337A2 (pt) | Compostos tricíclicos | |
| BR112015003033B1 (pt) | Composto, composição farmacêutica e uso do composto | |
| WO2023003973A1 (fr) | Inhibiteurs ciblant la protéase spécifique de l'ubiquitine 7 (usp7) | |
| EP4061819A1 (fr) | Dérivés indoles macrocycliques utilisés comme inhibiteurs de la mcl-1 | |
| WO2020124060A1 (fr) | Composés substitués par organophosphoré en tant qu'inhibiteurs de c-met et leurs utilisations thérapeutiques | |
| IL310412A (en) | 8-oxa-3-aza-dicyclo[3.2.1]octane compounds or their salt, method of preparation, and their use | |
| WO2022070071A1 (fr) | Inhibiteurs de la dihydroorotate déshydrogénase | |
| WO2023250082A2 (fr) | Inhibiteurs à petites molécules de dyrk/clk et leurs utilisations | |
| WO2021147790A1 (fr) | Dérivé de pyrazolo[1,5-a]pyrazine et procédé de préparation s'y rapportant et son utilisation | |
| CN110950868A (zh) | 吡唑并嘧啶化合物及制备方法与制备抗癌症药物的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 413/14 Ipc: C07D 413/14 (2006.01), C07D 471/04 (2006.01), A61P |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/08/2013, OBSERVADAS AS CONDICOES LEGAIS |